Edition:
United Kingdom

Iovance Biotherapeutics Inc (IOVA.OQ)

IOVA.OQ on NASDAQ Stock Exchange Global Market

14.90USD
20 Apr 2018
Change (% chg)

$-0.20 (-1.32%)
Prev Close
$15.10
Open
$14.95
Day's High
$15.25
Day's Low
$14.85
Volume
102,403
Avg. Vol
262,697
52-wk High
$19.80
52-wk Low
$4.45

Chart for

About

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program... (more)

Overall

Beta: 4.58
Market Cap(Mil.): $552.43
Shares Outstanding(Mil.): 70.37
Dividend: --
Yield (%): --

Financials

  IOVA.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -2.11 -- --
ROI: -49.36 1.58 14.38
ROE: -80.46 2.41 16.07

BRIEF-Iovance Biotherapeutics Announces Pricing Of Its Public Offering Of $150 Million Of Common Stock

* IOVANCE BIOTHERAPEUTICS, INC. ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF $150 MILLION OF COMMON STOCK

25 Jan 2018

BRIEF-Iovance Announces Preliminary Phase 2 Data For Til Treatment In Head And Neck And Cervical Cancers

* IOVANCE BIOTHERAPEUTICS ANNOUNCES PRELIMINARY PHASE 2 DATA FOR TIL TREATMENT IN HEAD AND NECK AND CERVICAL CANCERS

24 Jan 2018

BRIEF-Iovance Biotherapeutics‍ Intends To Offer And Sell $125 Mln Of Its Common Stock

* IOVANCE BIOTHERAPEUTICS, INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

24 Jan 2018

BRIEF-Iovance Biotherapeutics Files For Mixed Shelf Of Up To $250 Mln

* IOVANCE BIOTHERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING Source text: (http://bit.ly/2zKJhqw) Further company coverage:

28 Dec 2017

BRIEF-Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates

* IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017

13 Dec 2017

BRIEF-Iovance Biotherapeutics reports Q3 GAAP loss per share $0.35

* Iovance Biotherapeutics Inc reports third quarter 2017 financial results

31 Oct 2017

Earnings vs. Estimates